All In MedTech

Device Trial Radar · NCT06949969

Alesis OSA-1 Obstructive Sleep Apnea Treatment

Alesis OSA-1 Double-Blinded Randomized Study of Obstructive Sleep Apnea Treatment Using A Patented Noncoherent Medical Light

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

May 1, 2025

Primary completion

Nov 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
Photonica USA, LLCNot on our public-company list
Sponsor type
Industry
First posted
Apr 29, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of randomized clinical trial is to determine if the Alesis OSA-1 low laser light therapy device can reduce apnea-hypopnea index scores and treat sleep apnea in adult participants over the age of 18 who are diagnosed with obstructive sleep apnea (OSA). The main questions it aims to answer are\]: • Does the use of the Alesis OSA-1 device reduce the number of AHI events after six treatments of 12 minutes each, 2x per week x 3 weeks, in adult OSA patients? Researchers will compare results of 35 control group participants who will not receive treatment to a treatment group who will receive six, 12 minute, non-invasive low laser light therapy (LLLT) treatments, two per week for 3 weeks, to see if there is a reduction in the number of AHI events and size of redundant and soft tissues in adult OSA patients. Participants will: * Visit the clinic for assessment and instructions on using the at home sleep study system, WatchPat, and obtain baseline information * Use the WatchPat system to record AHI events pre- and post-treatment. * 10 randomly selected participants will receive a pre-study pulmonary functions test (PFT) and repeated post-treatment. * 5 randomly selected participant will receive a pre-study MRI of the head/neck and repeated post treatment. * For the treatments, the participant lie on a treatment table under a LLLT device for 12 minutes, two times per week, x 3 weeks. * Be offered the treatment series at the conclusion of the study if they were selected for the control group.

Conditions

  • Obstructive Sleep Apnea

Interventions

  • OSA LLLT treatment deviceDevice

    The Alesis OSA-1 is a LLLT that uses 635nm wavelength to stimulate the mitochondria to open cell spaces and allow oils, lipids, and fluids to drain into the body systems.

  • Sham ComparatorDevice

    A modified device utilizing a pigtail connector to bypass active treatment while allowing the cooling fans to operate for the treatment period, giving the appearance of treatment with invisible light.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AHI EventsTime frame: From enrollment until the end of treatment at 3 weeks.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • JD Medical Group, LLC

    Miami, Florida

  • Bioresearch Institute, Llc.

    Miramar, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.